Skip to main content(Press Enter).
The COVID-19 Coronavirus health crisis is presenting unprecedented challenges that are being felt worldwide and deep in the heart of our communities. At Combined Insurance, we have taken steps to protect our employees and their families while working to maintain solid levels of support and service for our customers
Start of main content
Alli Walsh, Social Media Strategist
What a great way to start the summer! On June 3rd, the American Society for Clinical Oncology released news to make our sunny summer days even brighter. According to a long-term, federally-funded study, thousands of women who are facing a breast cancer diagnosis won’t need to undergo chemotherapy and all its painful side effects, to achieve optimum results.1
When women are diagnosed with the most common form of breast cancer (called hormone receptor-positive, HER2-negative, axillary node-negative breast cancer) their doctors perform a genome test on the tumor to determine the Breast Recurrence Score. 2 Traditionally, women with a mid-range recurrence score (between 11-25) did not have a large study to help them or their doctors determine the best treatment course, so usually would choose the most aggressive option of treating it with chemotherapy and hormone therapy.
And, as we all know, chemotherapy’s side effects can be brutal for patients, causing nausea, fatigue, infection, hair loss, early menopause, infertility and neuropathy.1
A new study, called the Trial Assigning IndividuaLized Options for Treatment (TAILORx) has shed some light on this dilemma, empowering women and their doctors with the information they need to best treat their cancer.
The importance of the TAILORx study cannot be underestimated because it will spare thousands of women from receiving chemotherapy that wouldn’t benefit them. It was a well-designed study, enrolling 10,273 women and following them over 9 years.
Bottom line, the study demonstrates that:
And that’s GREAT news for women looking for an evidence-based reason to NOT use chemotherapy to treat their breast cancer. In the study, women with recurrence scores of 11-25 had a 93% survival rate after 9 years, with or without the chemo. 1
Another important finding of the study showed that women under 50 who had a recurrence score of 16-25 benefited slightly with the addition of chemotherapy to hormone replacement therapy.1
Next time you feel skeptical about donating to a cancer foundation, consider that this study was made possible by several well-known cancer foundations. The National Cancer Institute, part of the National Institutes of Health, was the primary funder of this study, but additional support was given by the Breast Cancer Research Foundation, Komen Foundation, and the U.S. Postal Service Breast Cancer Stamp .1
1 Most Women With Early Stage Breast Cancer Can Forgo Chemotherapy When Guided by a Diagnostic Test. (2018, June 03). Retrieved from asco.org/about-asco/press-center/news-releases/most-women-early-stage-breast-cancer-can-forgo-chemotherapy.
2 Oncotype DX: Genomic Test to Inform Breast Cancer Treatment. (n.d.). Retrieved from breastcancer.org/symptoms/testing/types/oncotype_dx.
Melanoma Awareness Month
Committing to Growth During the Pandemic: Building Resilience
Ways to Stay Safe and Healthy All Summer Long
Get protection from the hidden costs of accidents, illnesses and income disruption.
Offer your employees additional benefits with no extra cost to your company.
Learn more about our leadership, our vision and what we're doing.
“Start of statement by W. CLEMENT STONE, FOUNDERDo the right thing because it's the right thing to do.End of statement ”W. CLEMENT STONE, FOUNDER
Combined Insurance Company of America (Chicago, IL Illinois) is a leading provider of individual supplemental accident, disability, health, and life insurance products and a Chubb company. With a tradition of nearly 100 years of success, we have an A+ rating by the Better Business Bureau and are one of Ward’s Top 50® Performing Life-Health Insurance Companies. Combined Insurance is also the number one Military Friendly® Employer in the over $1B revenue category for 2019 by VIQTORY. This is the company’s eighth consecutive year on the top 10 list and fifth consecutive year in the top 5—Combined Insurance was previously named the number one Military Friendly® Employer in the nation for 2015 and 2016. In New York, products are underwritten by Combined Life Insurance Company of New York (Latham, NY).
Products & Solutions
© 2020 Combined Insurance. All rights reserved.